Given that IFNγ signalling, including Parp14 expression, was upregulated in tumours relapsing following α-PD-1 treatment, we next addressed whether these tumours were sensitive to Ruxolitinib (a JAK inhibitor) administered at a dose designed to suppress only tumour cell intrinsic IFNγ signalling9 as well as to RBN012759. This evidence concerns the gene PARP14 and neoplasm.